New York Magazine

Think Your Skin’s Too Sensitive for Acids? May We Suggest PHAs?

But because they penetrate more slowly and even more shallowly than AHAs, they typically cause less irritation and are often ...

Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis

ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill Approval supported by four phase 3 studies that met ...

This Tiny Patch Could Transform How Doctors Study Aging, Infections, and Vaccines

A bandage-like microneedle patch can noninvasively collect immune cells and signals from the skin within minutes to hours. Early tests suggest it could transform how immune responses are monitored.
MPR

FDA Approves Oral Icotrokinra for Moderate to Severe Plaque Psoriasis

Oral icotrokinra is now FDA-approved for plaque psoriasis, offering a new systemic option for adults and adolescents who weigh at least 40kg.
Medscape

FDA Approves Icotrokinra for Moderate-to-Severe Plaque Psoriasis

This is the first IL-23 receptor-targeted oral peptide pill, and it is also being evaluated as a treatment for psoriatic arthritis, ulcerative colitis, and Crohn’s disease.

FDA approves Johnson & Johnson’s oral pill for psoriasis, company says

The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's oral pill for psoriasis, the company said.
MedPage Today

'Potential Game Changer' for Psoriasis Gets Green Light From FDA

The FDA has approved the first oral interleukin (IL)-23-targeted therapy for plaque psoriasis, Johnson & Johnson announced. The approval of icotrokinra (Icotyde) stipulates use in adults and children ...
BioPharma Dive

J&J wins FDA nod for psoriasis pill that aims to compete with top-selling injections

The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J ...
Managed Healthcare Executive

FDA approves once daily pill Icotyde for plaque psoriasis

FDA approval covers adults and adolescents ≥12 years (≥88 lbs) with moderate-to-severe plaque psoriasis requiring systemic therapy or phototherapy, expanding systemic options beyond injectables.
Healio

FDA approves icotrokinra, first oral peptide for adults and teens with plaque psoriasis

The FDA approved icotrokinra for adults and adolescents aged 12 years and older with moderate to severe plaque psoriasis, Johnson & Johnson announced in a press release. Icotrokinra (Icotyde) is the ...
Becker's Hospital Review

FDA clears 1st oral pill for plaque psoriasis

The FDA clears 1st oral pill for plaque psoriasis, approving Johnson & Johnson’s Icotyde for adults and pediatric patients age 12 and older.
Fierce Pharma

J&J, Protagonist's 'game-changer' once-daily psoriasis pill Icotyde nabs FDA approval

Johnson & Johnson and Protagonist Therapeutics are countering the swarm of injectable biologics that have long dominated the lucrative psoriasis market with a new approval for a much-anticipate | The ...